Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18898-18914
DOI: 10.1021/acs.jmedchem.6c01182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.07.2026. Verfasst von Alina Ciammaichella und 27 weiteren Autor:innen. Beteiligte Einrichtung: IRBM S.P.A. Via Pontina Km 30.600, 00071PomeziaRome, Italy. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, ras Proteins, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Collezione Nazionale di Composti Chimici e Centro di screening.
Abstract (Originalsprache)
SHP2 (Src homology 2 (SH2)-containing protein tyrosine phosphatase 2) is a tyrosine phosphatase that plays a critical role in numerous physiological and pathological cellular processes, including cell proliferation, survival, and migration through the regulation of multiple signaling pathways, such as RAS-RAF-mitogen-activated protein kinase, phosphatidylinositol 3-kinase (PI3K)-AKT, Janus tyrosine kinase (JAK), and signal transducer and activator of transcription pathways (STAT) in response to cytokines and growth factors. Through extensive structure-based optimization, we identified I-0436650, a preclinical candidate with an excellent pharmacological profile. I-0436650 is a low nanomolar allosteric inhibitor of human wild-type (wt) SHP2 and strongly inhibits ERK phosphorylation in cells. It exhibits antiproliferative activity in EGFR- and RAS-dependent cell lines, suppresses tumor growth as a single agent in xenograft models, and delays tumor relapse when combined with inhibitors of the same pathway, demonstrating the potential of vertical inhibition strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IRBM S.P.A. Via Pontina Km 30.600, 00071PomeziaRome, Italy.
ORCID-Profile: Alina Ciammaichella, Esther Torrente, Jérôme Amaudrut, Annalise Di Marco, Simone Esposito
Förderung
- Collezione Nazionale di Composti Chimici e Centro di screening
Zitieren
APA
Ciammaichella, A., Puca, F., Fabbrini, D., Randazzo, P., Rossetti, I., Sferrazza, A., Ferrigno, F., Grillo, A., Torrente, E., Iaccarino, C., Amaudrut, J., Cellucci, A., Di Marco, A., Palombo, S., Esposito, S., Bisbocci, M., Orsale, M. V., Nibbio, M., Missineo, A., …, & Petrocchi, A. (2026). Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of Medicinal Chemistry, 69(15), 18898-18914. https://doi.org/10.1021/acs.jmedchem.6c01182
Vancouver
Ciammaichella A, Puca F, Fabbrini D, Randazzo P, Rossetti I, Sferrazza A, et al. Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of Medicinal Chemistry. 2026;69(15):18898-18914. doi:10.1021/acs.jmedchem.6c01182
BibTeX
@article{Ciammaichella2026,
author = {Ciammaichella, Alina and Puca, Francesca and Fabbrini, Danilo and Randazzo, Pietro and Rossetti, Ilaria and Sferrazza, Alessio and Ferrigno, Federica and Grillo, Alessandro and Torrente, Esther and Iaccarino, Costanza and Amaudrut, Jérôme and Cellucci, Antonella and Di Marco, Annalise and Palombo, Simone and Esposito, Simone and Bisbocci, Monica and Orsale, Maria Vittoria and Nibbio, Martina and Missineo, Antonino and Scalabrì, Francesco and Fodale, Valentina and Pucci, Vincenzo and Alli, Cristina and Di Fabio, Romano and Montalbetti, Christian and Carugo, Alessandro and Toniatti, Carlo and Petrocchi, Alessia},
title = {Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18898--18914},
doi = {10.1021/acs.jmedchem.6c01182}
}
EUVIMED